Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Trial details
- Registry ID
- NCT06843239
- Phase
- Phase 2
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)NCT06843239 | Zura Bio Inc | Phase 2 | Active not recruiting | 2027-05Estimated |
| Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610 | Zura Bio Inc | Phase 2 | Active not recruiting | 2026-11Estimated |
NCT06843239 · Zura Bio Inc
Recruiting
Active not recruiting
NCT06993610 · Zura Bio Inc
Recruiting
Active not recruiting
NCT06843239 · Zura Bio Inc
Dec 2026
May 2027
NCT06993610 · Zura Bio Inc
180 participants (planned)
225 participants (planned)
Sep 2026
Nov 2026
NCT06993610 · Zura Bio Inc
225 participants (planned)
180 participants (planned)
NCT06993610 · Zura Bio Inc
180 participants (planned)
225 participants (planned)